You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Dual View Endoscopy for Colonoscopy

    SBC: OMNISCIENT IMAGING INC            Topic: 102

    AbstractAn estimatedmillion colonoscopies are performed annually in the US at a cost of about $Bhowever current colonoscopes with forward vision fail to detectof precancerous polypsOverof the missed polyps are located on or behind numerous folds in the colon where they are hidden from the sight of a forward view colonoscopeIn this research proposalwe propose to complete our development of an imagi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. DNA Quadruplex Control of hTERT Transcription: A New Therapy for Taxotere Resistant Prostate Cancer

    SBC: Reglagene, LLC            Topic: 102

    PROJECT SUMMARYTelomerase maintains telomere length and prevents cellular senescenceIt is upregulated inof cancerssuppressed in most non cancer tissuesand is a primary driver of tumor cell immortalityNo clinical agent acting on telomerase has been approved for human useA hurdle for approaches that directly inhibit the action of telomerase is that therapeutic effect is observed only after many popu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThe Aurora Kinase FamilyAKFcomprises heavily pursued therapeutic targets for cancer because of their intimate involvement in cell division and tumor progressionNumerous therapeutic campaigns have been initiated against the AKFwith promising clinical successes emanating from strategies targeting either Aurora A or Aurora BHoweverthe US Food and Drug Administration has yet to approve a cance ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Continuous emulsion digital PCR (cdPCR) for low-cost, rapid, near point-of-care genotyping of non-small cell lung cancer

    SBC: DropWorks, Inc.            Topic: 102

    PROJECT SUMMARY Genotyping of cancer has become the standard of carewhere specific mutations in cancer driving genes have been shown to indicate sensitivity or resistance to targeted treatmentsSampling of cell free DNAcfDNAin blood plasma could provide a non invasive means of performing this genotypingbut current methods are too complexslowdaysand expensivehundreds of dollarsto make use of this in ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS

    SBC: RESTORE THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARYAcute Respiratory Distress SyndromeARDSis a devastating syndrome that afflicts more thanpatients in United States alone and has an unacceptably high mortality rate ofCurrently there are no therapies that address the loss of lung vascular barrier integrityvascular leakage and alveolar flooding that are critical features of ARDS pathobiologyThe PI was the first to demonstrate that sph ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Slip Flow Chromatography

    SBC: BIOVIDRIA, INC.            Topic: 100

    DESCRIPTION provided by applicant The goal of this STTR Phase II collaboration between Purdue University and bioVidria Inc is to commercialize disruptive new technology for protein chromatography and then maximize its impact by serving the fastest growing segment of the pharmaceutical industry protein drugs The product is a reversed phase chromatography column that uses silica particles of ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)

    SBC: IRON HORSE DIAGNOSTICS, INC.            Topic: 101

    DESCRIPTION provided by applicant Amyotrophic lateral sclerosis ALS or Lou Gehrigandapos s disease is a fatal neurodegenerative disease with a typical lifespan of years after diagnosis The initial symptoms can be similar to many other neurologic disorders and often begin with limb weakness muscle fasciculations or increasing difficulties in speech or breathing No definitive diagnost ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Surface-covering gels for broad-spectrum antimicrobial protection following open

    SBC: SONORAN BIOSCIENCES INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): About 3-4% of all fractures are estimated to be open fractures, where the fracture is exposed through defects in the skin and soft tissues. This equates to about 250,000 open fractures in the United States annually. Open fractures present a high risk of infection. Infection results in considerable financial burden to both the patient an healthcare system, requ ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government